Ironwood Pharmaceuticals

Media

Business Woman speaking in an office presentation
looking down at two laptops in use in an office
Media Inquiries

Beth Calitri

Corporate Communications, Media Relations
978.417.2031
[email protected]

Social
Linkedin Twitter

  • Sort by Year

Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application forLINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application forLINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age

AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age
Ironwood Pharmaceuticals Home
Linkedin Twitter